Vesalius Therapeutics employs a proprietary platform that utilizes patient-derived, cell-based experimental models and advanced data analytics to identify novel drug targets for complex diseases like heart failure and type II diabetes. By recognizing distinct clinical patterns linked to genetic variations, the company aims to develop targeted therapies that address the multifaceted nature of these prevalent illnesses.
Funding
$75M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many common diseases, such as heart failure, type II diabetes, and Alzheimer's, are currently diagnosed as single entities, despite being composed of multiple genetically and biologically distinct subtypes that affect patients differently. This lack of precise diagnosis hinders the development of effective, targeted therapies.
Solution
Vesalius Therapeutics is developing a platform to reconceptualize how common diseases are viewed, diagnosed, and treated. The platform identifies previously unrecognized clinical patterns in patient groups, links these patterns to the combined effects of multiple genes comprising gene circuits, and identifies circuit dependencies that are novel and optimal drug targets. Vesalius utilizes proprietary patient-derived, cell-based experimental models to screen and characterize drug candidates to restore these circuits to healthy functioning, leveraging data science, AI, machine learning, human genetics, and genomics.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing treatments for common diseases like heart failure, type II diabetes, and Alzheimer's.
Features
- Patient-derived, cell-based experimental models for drug screening and characterization
- AI and machine learning-driven analysis of patient data to identify clinical patterns
- Identification of novel drug targets by linking clinical patterns to gene circuit effects
- Screening of drug candidates to restore gene circuits to healthy functioning